Topics, Trends & Updates
October 2022
Updated: HCV Care Guidelines
Updated: Perinatal HIV Care
New York State Good Practices: Newborn HIV Testing: A nucleic acid test (NAT) to detect HIV RNA or DNA will provide early diagnosis of pediatric HIV infection. Good practice in NYS is to perform an HIV NAT test in an infant at the following ages:
  • Within 48 hours of birth
  • 2 weeks of age
  • 4 to 6 weeks of age
  • 8 to 12 weeks of age
  • 4 to 6 months of age
The NYSDOH strongly advises that all NYS birth facilities use the pediatric HIV testing services at the Wadsworth Center; the services are free of charge for those receiving testing and for NYS clinicians who provide care for HIV-exposed infants.

Updated: Pneumococcal Vaccination for Adults With HIV
Individuals with HIV are at increased risk of serious disease due to Streptococcus pneumoniae, including bacteremia, meningitis, and pneumonia. Pneumococcal vaccination is recommended for all adults with HIV as soon as possible after HIV diagnosis.

Pneumococcal vaccination should not be deferred for patients with CD4 count <200 cells/mm3 and/or detectable viral load; however, the follow-up secondary administration of the PPSV23 vaccine may be deferred until the patient’s CD4 count is >200 cells/mm3 and/or viral load is undetectable.
Available Vaccines
  • PCV15: 15-valent pneumococcal conjugate vaccine (Vaxneuvance)
  • PCV20: 20-valent pneumococcal conjugate vaccine (Prevnar 20)
  • PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23)
Indication and Administration
  • All patients with HIV
  • For patients who have not received a pneumococcal conjugate vaccine or whose vaccination status is unknown: Administer 1 dose of PCV15 or 1 dose of PCV20. If PCV15 is used, follow with 1 dose of PPSV23, with a minimum interval of 8 weeks between the doses.
Hot Topics
Some Basics About HIV-Hepatitis B Coinfection: HIV and Hepatitis B share similar routes of transmission. In the United States, a large cohort study of patients with HIV showed that over 10% of men who had sex with men, over 8% of those who injected drugs and over 5% of heterosexual individuals with risk factors tested positive for HBsAg or detectable HBV DNA. Because of the shared transmission routes, there is an increased risk of HIV and HBV co-infection. Despite the advancement of ART, which has a very efficient suppression rate of the HIV and HBV replication, morbidity and mortality rates are still higher in patients with HIV-HBV co-infection. In this episode, Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester and Anthony Jordan Health Center, speaks about the management of Hepatitis B in patients with HIV.
Journal of Public Health Management Editor's PodcastThe Impact of a PrEP Aware Week Campaign on PrEP Prescription Refills in New York State: Article authors describe an effective and replicable intervention that increased PrEP prescription fills across multiple subgroups.
Upcoming Training, Education, and Events
Are You a Subscriber?
If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program news every month and stay current with new and updated guidelines.

Subscribing is as easy as entering your email address. We will send you just 1 email per month, and we do not share our mailing list.
Please subscribe now!
Comment? Question? Suggestion? Drop us a line: We welcome feedback and suggestions, and if you send us a question, we will get back to you as quickly as possible. Please note, however, that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice.